<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04559971</url>
  </required_header>
  <id_info>
    <org_study_id>SLN124-003</org_study_id>
    <nct_id>NCT04559971</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study to Evaluate the Safety, Tolerability, PK and PD of SLN124 in Healthy Volunteers</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled Phase 1 Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SLN124 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Silence Therapeutics plc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Silence Therapeutics plc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and tolerability of SLN124 in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This first-in-human (FIH) study will investigate the safety, tolerability, pharmacokinetics&#xD;
      (PK) and pharmacodynamics (PD) of SLN124 after single ascending s.c. doses in healthy male&#xD;
      and female subjects.&#xD;
&#xD;
      Up to 3 cohorts of 24 healthy volunteers will be enrolled. Each subject will receive a single&#xD;
      dose of SLN124 or placebo given by subcutaneous (s.c) injection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 3, 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>8 weeks</time_frame>
    <description>safety and tolerability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic: peak plasma concentration (Cmax)</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic: area under the plasma concentration (AUC)</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic: apparent total clearance from plasma after s.c injection (CL/F)</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Pharmacodynamic: change in ferritin</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacodynamic: change in TSAT</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacodynamic: change in hepcidin</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacodynamic: change in haemoglobin</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>1.0mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: SLN124</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3.0mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: SLN124</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optional Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>An additional dose level may be explored</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SLN124</intervention_name>
    <description>SLN124 for subcutaneous (s.c.) injection</description>
    <arm_group_label>1.0mg/kg</arm_group_label>
    <arm_group_label>3.0mg/kg</arm_group_label>
    <arm_group_label>Optional Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sodium chloride for s.c. injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Normotensive male or female volunteers, with a body mass index of 18.0-30.0 kg/m2.&#xD;
&#xD;
          -  Deemed healthy on the basis of a clinical history, physical examination, ECG, vital&#xD;
             signs, and laboratory tests of blood and urine.&#xD;
&#xD;
          -  Agree to follow the contraception requirements of the trial.&#xD;
&#xD;
          -  Able to give fully informed written consent.&#xD;
&#xD;
          -  Agree not to donate blood or blood products during the study and for up to 3 months&#xD;
             after the administration of the trial medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or presence of iron deficiency or iron deficiency anaemia and/or currently&#xD;
             receiving oral or parenteral iron supplementation as treatment for those conditions.&#xD;
&#xD;
          -  Positive tests for hepatitis B &amp; C, HIV&#xD;
&#xD;
          -  Drug or alcohol abuse.&#xD;
&#xD;
          -  Smoke more than 10 cigarettes (or equivalent) daily.&#xD;
&#xD;
          -  Use of over-the-counter medication (with the exception of paracetamol [acetaminophen])&#xD;
             during the 7 days before the first dose of trial medication, or prescribed medication&#xD;
             (with the exception of hormone replacement therapy [HRT]) during the 28 days before&#xD;
             first dose of trial medication.&#xD;
&#xD;
          -  Use of supplement(s) during the 28 days before screening.&#xD;
&#xD;
          -  Participation in other clinical trials of unlicensed medicines, or loss of more than&#xD;
             400 mL blood, within the previous 3 months.&#xD;
&#xD;
          -  Clinically relevant abnormal medical history or concurrent medical condition.&#xD;
&#xD;
          -  Pre-menopausal females who are pregnant or lactating, or who are sexually active and&#xD;
             not using a reliable method of contraception.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giles Campion, MD</last_name>
    <role>Study Director</role>
    <affiliation>Silence Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hammersmith Medicines Research</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 8, 2020</study_first_submitted>
  <study_first_submitted_qc>September 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2020</study_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

